case_images: PMC9215205_01
case_images: Here is reported the timeline of poziotinib administration and the related toxicities.
case_images: fonc-12-902967-g001.jpg
case_images: PMC9215205_01_fonc-12-902967-g001.jpg
case_images: f1
case_images: In  Figure 1 , the timeline of poziotinib administration with the resulting side effects is reported.
case_images: CT scans performed on January 2021 [(A), baseline poziotinib] and subsequently on March 2021 (B) and October 2021 (C) demonstrated a PR (B) and a disappearance of the lesion (C).
case_images: fonc-12-902967-g002.jpg
case_images: PMC9215205_01_fonc-12-902967-g002.jpg
case_images: f2
case_images: Then, in October 2021, CT scan confirmed a CR (reduction on tumour size of 100%) on both the liver and the retroperitoneal nodes ( Figure 2 ).
case_images: This figure demonstrated the exact lesions selected as target lesion for central and local radiological review.
case_images: fonc-12-902967-g003.jpg
case_images: PMC9215205_01_fonc-12-902967-g003.jpg
case_images: f3
case_images: The graphics showed the local (A) and the central review (B) of the RECIS 1.1 criteria.
case_images: fonc-12-902967-g004.jpg
case_images: PMC9215205_01_fonc-12-902967-g004.jpg
case_images: f4